NeoGenomics EVP converts RSUs, withholds shares for tax
NeoGenomics EVP, GC & Business Development Alicia C. Olivo reported equity award activity.
Rhea-AI Filing Summary
NeoGenomics EVP, GC & Business Development Alicia C. Olivo reported equity award activity. On February 21 and 23, 2026, she converted a total of 29,522 restricted stock units into an equal number of NeoGenomics common shares at no cash exercise price. To cover tax withholding on these vestings, 11,618 common shares were disposed of through share withholding rather than open-market sales. After these transactions, she directly held 93,224 shares of common stock, alongside multiple outstanding stock option, restricted stock unit, and performance stock unit awards that continue to vest over time.
Positive
- None.
Negative
- None.
Insider Trade Summary
29,522 shares exercised/converted
Exercise
19 txns
Insider
Olivo Alicia C
Role
EVP, GC & Business Development
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 8,443 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,443 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 3,323 | $0.00 | $0.00 |
| Exercise | Restricted Stock Unit | 21,079 | $0.00 | $0.00 |
| Exercise | Common Stock | 21,079 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 8,295 | $0.00 | $0.00 |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Performance Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Performance Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Unit — 116,487 contracts for 65,885 underlying shares (Direct);
Common Stock — 93,224 shares (Direct);
Stock Option (Right to Buy) — 258,582 contracts (Direct);
Performance Stock Unit — 44,838 contracts (Direct)
Footnotes (18)
- F1. Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.
- F2. Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
- F3. On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
- F4. Once vested, the shares of common stock are not subject to expiration.
- F5. On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
- F6. On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F7. On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F8. On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F9. On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F10. On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F11. On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- F12. On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- F13. On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
- F14. On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
- F15. On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- F16. On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
- F17. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
- F18. On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did NeoGenomics (NEO) report for Alicia C. Olivo?
NeoGenomics reported that EVP, GC & Business Development Alicia C. Olivo converted restricted stock units into common stock and had shares withheld to cover taxes. These were equity award vesting and tax-withholding events, not open-market stock purchases or sales.
What ongoing equity awards does Alicia C. Olivo have at NeoGenomics (NEO)?
The filing shows Ms. Olivo holds multiple stock options, restricted stock units, and performance stock units. Footnotes explain these awards generally vest ratably over three or four years and, for performance units, depend on share price and revenue growth goals being achieved.
How do the reported NeoGenomics RSUs for Alicia C. Olivo vest over time?
Footnotes state that several RSU grants to Ms. Olivo, including 63,238 units granted on February 21, 2025 and 25,329 units granted on February 23, 2024, vest ratably over the first three anniversaries of their grant dates, subject to her continued service with the company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
